BAG-1 expression in hyperplastic and neoplastic prostate tissue: Is there any relationship with BCL-related proteins and androgen receptor status?

Tumori

Volumn 91, Issue 6, 2005, Pages 539-545

  Bozdoǧan, Önder ^a   Atasoy, Pinar ^a   Bozdoǧan, Nazan ^b   Erekul, Selim ^c   Batislam, Ertan ^a   Yilmaz, Erdal ^a   Başar, M Murad ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b ANKARA ONCOLOGY HOSPITAL   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Apoptosis; BAG 1; BAX; BCL 2; Chromogranin A; Prostate carcinoma

Indexed keywords

ANDROGEN RECEPTOR; AVIDIN; BAG 1 PROTEIN; BIOTIN; CHROMOGRANIN A; MONOCLONAL ANTIBODY; PEROXIDASE; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; EARLY DIAGNOSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 32844465932     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160509100615     Document Type: Article

References (33)

1. Mazhar D, Waxman J: Prostate cancer. Postgrad Med J, 78: 590-595, 2002.
2. Tang DG, Porter AT: Target to apoptosis: A hopeful weapon for prostate cancer. Prostate, 32: 284-293, 1997.
3. Reiter RE, deKernion JB: Epidemiology, etiology, and prevention of prostate cancer. In: Campbell's Urology, 8th ed, vol 4, Walsh PC, Retik AB, Vaughan ED, Wein AJ (Eds), pp 3003-3024, Saunders, Philadelphia, 2002.
4. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J: Molecular genetics and epidemiology of prostate carcinoma. Endoc Rev, 20: 22-45, 1999.
5. Culg Z, Hobisch A, Bartsch G, Klocker H: Expression and function of androgen receptor in carcinoma of prostate. Microsc Res Tech, 51: 447-455, 2000.
6. Montgomery JS, Price DK, Figg WD: The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol, 195: 138-146, 2001.
7. Danial NN, Korsmeyer SJ: Cell death: Critical control points. Cell, 116: 205-219, 2004.
8. Lu Q, Abel P, Foster C, Lalani EN: Bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol, 27: 102-110, 1996.
9. Schultz DR, Harrington WJ: Apoptosis: Programmed cell death at molecular level. Sem Art Rheum, 32: 345-369, 2003.
10. Morsi HM, Leers MP, Jager W, Bjorklund V, Radespiel-Troger M, el Kabarity H, Nap M, Lang N: The patterns of expression of an apoptosis related CK18 neoepitope, the bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic and malignant endometrium. Int J Gynecol Pathol, 19: 118-126, 2000.
11. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: A novel Bcl-2 binding protein with anti-cell death activity. Cell, 80: 279-284, 1995.
12. Froesch BA, Takayama S, Reed JC: BAG-1L protein enhances androgen receptor function. J Biol Chem, 273: 11660-11666, 1998.
13. Doong H, Vrailas A, Kohn EC: What's in the 'BAG'? A functional analysis of the BAG-family proteins. Cancer Lett, 188: 25-32, 2002.
14. Rosai J, Ackerman LV: Prostate and seminal vesicles. In: Rosai and Ackerman's Surgical Pathology, 9th ed, vol 1, pp 1361-1412, Mosby, Philadelphia, 2004.
15. Foster CS, Bostwick DG: Pathology of the prostate. Major Problems in Pathology Series 34, WB Saunders Company, Philadelphia, 1998.
16. Epstein JI: The prostate and seminal vesicles. In: Diagnostic surgical pathology, 4th ed, Mills SE (Ed), pp 2083-2133, Lippincott Williams & Wilkins, Philadelphia, 2004.
17. Nyholm HCJ, Nielsen AL, Lyndrup J, Driesler A, Thorpe SM: Estrogen and progesterone receptors in endometrial carcinoma: comparison of immunohistochemical and biochemical analysis. Int J Gynecol Pathol, 12: 246-252, 1993.
18. Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM, Kochel K, Knee D, Scudiero D, Tudor G, Miller GJ, Miyashita T, Yamada M, Reed JC: Expression and localization of Hsp70/Hsc binding anti-apoptotic protein BAG-1 and its variants in normal tissues and tumor cell lines. Cancer Res, 58: 3116-3131, 1998.
19. Nessler-Menardi C, Jotova I, Culig Z, Eder IE, Putz T, Bartsch G, Klocker H: Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate, 45: 124-131, 2000.
20. Tang SC, Beck J, Murphy S, Chernenko G, Robb D, Watson P, Khalifa M: BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma. Breast Cancer Res Treat, 84: 203-213, 2004.
21. Sjostrom J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Wist E, Valvare V, Takayama S, Reed JC, Saksela E: The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res, 8: 811-816, 2002.
22. Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG, Adamson E, Reed JC: Expression of multiple apoptosis regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat, 47: 129-140, 1998.
23. Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA, Carter D, Rebbeck TR, Haffty BG, Reed JC: BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol, 19: 992-1000, 2001.
24. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kakuda K, Kuma K, Miyauvhi A: Bag-1 expression in thyroid neoplasm: its correlation with Bcl-2 expression and carcinoma dedifferentiation. Anticancer Res, 23: 569-576, 2003.
25. Sohn JH, Kim DH, Choi NG, Park YE, Ro JY: Caspase-3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias. Histopathology, 37: 555-560, 2000.
26. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC: Expression of Bcl-2, Bax and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate, 37: 223-229, 1998.
27. Erbersdobler A, Fritz H, Schnöger S, Graefen M, Hammerer P, Huland H, Henke RP: Tumor grade, proliferation, apoptosis, microvessel density, p53 and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol, 41: 40-46, 2002.
28. Krajewska M, Krajewski S, Epstein JI, Skabaik A, Sauvageot J, Song Ki, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, Bax, bcl-x, and mcl-1 expression in prostate cancers. Am J Pathol, 148: 1567-1576, 1996.
29. Chia SJ, Tang WY, Elnatan J, Yap WM, Goh HS, Smith D: Prostate tumours from an Asian population: Examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker. Br J Cancer, 83: 761-768, 2000.
30. Abrahamsson PA: Neuroendocrine differentiation in prostatic carcinoma. Prostate, 39: 135-148, 1999.
31. Segal N, Cohen R, Haffejee Z, Savage N: BCL-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med, 118: 616-618, 1994.
32. Salido M, Vilches J, Lopez A, Roomans GM: Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines. Cancer, 94: 368-377, 2002.
33. Fixemer T, Remberger K, Bonkhoff H: Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate, 53: 118-123, 2002.